The FDA approved the PD-1 inhibitor penpulimab, with two indications, for treating non-keratinizing nasopharyngeal carcinoma ...

The antibody is to treat adult recurrent or metastatic non-keratinising nasopharyngeal carcinoma (NPC) in conjunction with ...

Penpulimab is approved for multiple indications in China, but this marks the first US approval for the novel monoclonal ...

Shares of biotech companies involved in the development of monoclonal antibody cancer therapies were moving all over the ...

Persistent Epstein-Barr virus DNA or its resurgence during treatment was associated with worse survival in patients with ...

Approval of penpulimab-kcqx marks the company’s US regulatory debut and introduces a new immunotherapy option for advanced ...

Researchers with City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the U.S. with its National Medical Center named top 5 in the nation for cancer by U.

Following a positive readout for its closely watched PD-1xVEGF bispecific ivonescimab, Akeso has won the FDA’s go-ahead for ...

Penpulimab has picked up a pair of approvals in nasopharyngeal carcinoma (NPC), becoming only the second drug to be cleared ...

The company’s lead candidate, ivonescimab, aimed at treating certain cancers, was discovered by Akeso and is currently in ...

The FDA has approved Akeso Inc.’s penpulimab-kcqx in combination with cisplatin or carboplatin and gemcitabine for the first-line treatment of adult recurrent or metastatic NPC.